

7231 Parkway Drive, Suite 100, Hanover, MD 21076

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

USFHP Pharmacy Prior Authorization Form

To be completed by Requesting provider				
Drug Name:	Strength:			
Dosage/Frequency (SIG):	Duration of Therapy:			

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Prior authorization does not expire.								
Step	Please complete patient and physician information (please print):							
1	Patient Name:	Physician Name: Address: Phone #:						
	Address:							
	Sponsor ID #:							
Cton	Date of Birth: Secure Fax #:							
Step	Please complete the clinical assessment:	Please complete the clinical assessment:						
2	Is the patient greater than or equal to 18 years of age?	☐ Yes Proceed to question 2	□ No STOP Coverage not approved					
	Is the requested medication being prescribed by or in consultation with hematologist/oncologist or urologist?	☐ Yes Proceed to question 3	□ No STOP Coverage not approved					
	3. For which indication is the requested medication being prescribed?	□ Deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC)– proceed to question 4 □ Other - proceed to question 7						
	4. Is the patient using the requested medication concurrently with a gonadotropin-releasing hormone (GnRH) analog (for example, leuprolide, Eligard, Triptorelin, Goserelin)?	☐ Yes Proceed to question 6	□ No Proceed to question 5					
	5. Has the patient had a bilateral orchiectomy?	□ Yes Proceed to question 6	□ No STOP Coverage not approved					

TRICARE Prior Authorization Request Form for niraparib/abiraterone acetate (Akeega)

	6.	Will the requested medication be used in combination with prednisone?	Procee	□ Yes ed to question 9	□ No STOP Coverage not approved
	7.	Please provide the diagnosis.		Proceed to	question 8
	8.	Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	Procee	□ Yes ed to question 9	□ No STOP Coverage not approved
	9.	Will male patients with female partners use effective contraception during treatment and for 4 months after the last dose?	 □ Yes - proceed to question 10 □ No - STOP Coverage not approved □ Not applicable - proceed to question 10 		
	10.	Is the provider aware of the warnings, screening and monitoring precautions for the requested medication?	Sign a	☐ Yes and date below	□ No STOP Coverage not approved
Step 3	l c	ertify the above is true to the best of my l	knowledge		date:
		Prescriber Signature		Date	[14 Feb 2024]
For Inte	rnal	Use Only			
Appro	Approved:			Duration of Approval:month(s)	
☐ Denied:			Authorized By:		
☐ Incomplete/Other:			PA#:		
Date Faxed to MD:			Date Decision Rendered:		